Latest Health News

Western Gold Resources has formalised critical road access agreements enabling ore haulage from its Gold Duke Project to nearby processing facilities, marking a significant step forward in project development.

Biotron Limited reveals that its lead antiviral candidate BIT-HBV001 shows promising activity against Hepatitis Delta Virus, expanding its potential impact beyond Hepatitis B. Meanwhile, the company completes integration of Sedarex and advances regulatory plans for its anaesthetic SedRx.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.

First Lithium Limited’s shares have been suspended from trading on the ASX due to a missed reporting deadline, raising questions about the company’s compliance and near-term outlook.

West African Resources has reported a robust A$567 million net profit after tax for 2025, driven by strong gold production and operational cash flow. The successful ramp-up of the Kiaka gold production centre and sustained output from Sanbrado underpin the company’s positive outlook for 2026.

InteliCare Holdings has appointed seasoned healthcare executive Angus Cameron as CEO to lead its transition from pilot projects to full-scale commercial deployment following a major aged care contract.

Resonance Health has received a $732,851 refund from the Australian Taxation Office, reflecting its FY2025 R&D tax incentive claim net of income tax payable. This cash inflow strengthens the company’s financial position ahead of its March quarterly report.

BlinkLab has completed onboarding its tenth and final clinical site for its pivotal FDA 510(k) trial of an AI-powered autism diagnostic aid, setting the stage for patient enrolment to begin this month.

Racura Oncology has secured governance approval to launch its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib in EGFR-mutated non-small cell lung cancer patients. This milestone sets the stage for a potentially pivotal new approach to overcoming resistance in lung cancer treatment.

Calix Limited has successfully completed the first milestone of its ARENA grant for the Zesty Green Iron Demonstration Project, unlocking a $2 million payment and marking a key step forward in its industrial decarbonisation efforts.

Bio-Gene has signed a term sheet with Sumitomo Corporation and Nakashima Trading to introduce its 100% natural insecticide Qcide® to Japan’s $1 billion household pest market, aiming for a late 2026 launch.